News

News and Press Releases
About the CF Foundation | Drug Pipeline | Antibiotics FDA Approves New Powder Form of CF Drug TOBI®

The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).

| 1 min read